The anti-inflammatory and organ-protective effects of pentoxifylline during cardiac surgery

Applied Cardiopulmonary Pathophysiology

Volumn 11, Issue 2, 2007, Pages 17-23

  Heringlake, Matthias ^a   Heinrichs, G ^a   Weber, C F ^b   Rosemann, C ^a   Bahlmann, L ^a   Eichler, W ^a   Misfeld, M ^a   Heinze, H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cardiopulmonary bypass; Cardiovascular surgery; Immuno modulation; Phosphodiesterase inhibition

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTOXIFYLLINE; THIOPENTAL; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BLOOD RHEOLOGY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART SURGERY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LUNG EDEMA; MULTIPLE ORGAN FAILURE; NEWBORN SEPSIS; NONHUMAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 39649123463     PISSN: 09205268     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Asimakopoulos G, Gourlay T (2003) A review of anti-inflammatory strategies in cardiac surgery. Perfusion 18 (Suppl 1): 7-12
2. Sakaguchi T, Hayashi S (1978) Pharmacology and clinical trials of pentoxifylline. Pharmacometrics 15: 153-183
3. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 37 (1): 25-8
4. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34 (1): 50-97
5. Argel MI, Vittone L, Grassi AO, Chiappe LE, Chiappe GE, Cingolani HE (1980) Effect of phosphodiesterase inhibitors on heart contractile behaviour, protein kinase activity and cyclic nucleotide levels. J Mol Cell Cardiol 12 (10): 939-54
6. Vittone L, Chiappe LE, Argel MI, Cingolani HE, Chiappe GE (1980) The mechanical and biochemical effects of pentoxifylline on the perfused rat heart. Experientia 36 (9): 1088-90
7. Watanabe H, Furukawa Y, Chiba S (1982) Cardiovascular effects of aminophylline and pentoxifylline on intact dogs and isolated dog atria. Jpn Heart J 23 (2): 235-43
8. Schreiber P, Schröppel M, Heidrich H (1983) Effects of naftidrofuryl, pentoxifylline and bencyclane on the renal blood flow and renal excretion of conscious dogs. Herz 15: 195-201
9. Schade UF, von der Bosch J, Schonharting M (1989) Pentoxifylline increases survival of mice in endotoxic shock. Prog Clin Biol Res 301: 223-7
10. Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB (2005) Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 59 (3): 575-82
11. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R (2002) Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaB-sensitive pathway in alveolar epithelial cells. J Pharmacol Exp Ther 300 (2): 567-76
12. Wang W, Tam WF, Hughes CC, Rath S, Sen R (1997) c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6 (2): 165-74
13. Wang P, Ba ZF, Morrison MH, Ayala A, Chaudry IH (1992) Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery 112 (2): 451-7; discussion 457-8
14. van Leenen D, van der Poll T, Levi M et al. (1993) Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 151 (4): 2318-25
15. Coimbra R, Porcides RD, Melbostad H et al. (2005) Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg Infect (Larchmt) 6 (1): 73-85
16. Coimbra R, Melbostad H, Loomis W et al. (2006) LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. J Trauma 60 (1): 115-25
17. Trajkovic V, Badovinac V, Popadic D, Hadzic O, Stojkovic MM (1997) Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression. Immunology 92 (3): 402-6
18. Barroso-Aranda J, Schmid-Schonbein GW (1990) Pentoxifylline pretreatment decreases the pool of circulating activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock. Biorheology 27 (3-4): 401-18
19. Yada-Langui MM, Coimbra R, Lancellotti C et al. (2000) Hypertonic saline and pentoxifylline prevent lung injury and bacterial translocation after hemorrhagic shock. Shock 14 (6): 594-8
20. Bessler H, Gilgal R, Djaldetti M, Zahavi I (1986) Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 40 (6): 747-54
21. Coe DA, Freischlag JA, Johnson D et al. (1997) Pentoxifylline prevents endothelial damage due to ischemia and reperfusion injury. J Surg Res 67 (1): 21-5
22. Silomon M, Pizanis A, Larsen R, Rose S (1998) Pentoxifylline prevention of altered hepatocyte calcium regulation during hemorrhagic shock/resuscitation. Crit Care Med 26 (3): 494-500
23. Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN (1998) Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 111 (2): 300-8
24. Wenisch C, Looareesuwan S, Wilairatana P et al. (1998) Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 58 (3): 343-7
25. Weber F, Polak T, Gunther A et al. (1998) Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 44 (1): 27-34
26. Rieckmann P, Weber F, Gunther A, Poser S (1996) The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Neurology 47 (2): 604
27. Noel C, Hazzan M, Coppin MC et al. (1997) A randomized controlled trial of pentoxifylline for the prevention of delayed graft function in cadaveric kidney graft. Clin Transplant 11 (3): 169-73
28. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (6): 1637-48
29. Friedrich M, Sterry W, Klein A, Ruckert R, Docke WD, Asadullah K (2001) Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Derm Venereol 81 (6): 429-30
30. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P (2002) The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4 (3): 305-9
31. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P (1998) Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351 (9109): 1091-3
32. Sliwa K, Woodiwiss A, Candy G et al. (2002) Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 90 (10): 1118-22
33. Sliwa K, Woodiwiss A, Kone VN et al. (20049 Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109 (6): 750-5
34. Kowalski J, Kosmider M, Pasnik J et al. (1999) Pentoxifylline decreases neutrophil respiratory bursts in patients with stable angina. Fundam Clin Pharmacol 13 (2): 237-42
35. Lauterbach R, Zembala M (1996) Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 155 (5): 404-9
36. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M (1999) Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 27 (4): 807-14
37. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P (1998) Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 133 (1): 94-100
38. Koul BL, Nordhas O, Sonnenfeld T, Ekestrom S (1984) The effect of pentoxifylline on impaired red cell deformability following open-heart surgery. Scand J Thorac Cardiovasc Surg 18 (2): 129-31
39. Golbasi I, Akbas H, Ozdem S et al. (2006) The effect of pentoxifylline on haemolysis during cardiopulmonary bypass in open-heart surgery. Acta Cardiol 61 (1): 7-11
40. Butler J, Baigrie RJ, Parker D et al. (1993) Systemic inflammatory responses to cardiopulmonary bypass: a pilot study of the effects of pentoxifylline. Respir Med 87 (4): 285-8
41. Kleinschmidt S, Bauer M, Grundmann U, Schneider A, Wagner B, Graeter T (1997) Effect of gamma-hydroxybutyric acid and pentoxifylline on kidney function parameters in coronary surgery interventions. Anaesthesiol Reanim 22 (4): 102-7
42. Turkoz R, Yorukoglu K, Akcay A et al. (1996) The effect of pentoxifylline on the lung during cardiopulmonary bypass. Eur J Cardiothorac Surg 10 (5): 339-46
43. Tsang GM, Allen S, Pagano D, Wong C, Graham TR, Bonser RS (1996) Pentoxifylline preloading reduces endothelial injury and permeability in cardiopulmonary bypass. Asaio J 42 (5): M429-34
44. Ege T, Arar C, Canbaz S et al. (2004) The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 52 (1): 10-5
45. Cagli K, Ulas MM, Ozisik K et al. (2005) The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass. Perfusion 20 (1): 45-51
46. Ustunsoy H, Sivrikoz MC, Bakir K et al. (2002) The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung. Respir Med 96 (4): 275-9
47. Ustunsoy H, Sivrikoz MC, Tarakcioglu M, Bakir K, Guldur E, Celkan MA (20069 The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J Card Surg 21 (1): 57-61
48. Iskesen I, Saribulbul O, Cerrahoglu M, Onur E, Destan B, Sirin BH (2006) Pentoxifylline affects cytokine reaction in cardiopulmonary bypass. Heart Surg Forum 9 (6): E883-7
49. Boldt J, Brosch C, Lehmann A, Haisch G, Lang J, Isgro F (2001) Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 71 (5): 1524-9
50. Boldt J, Brosch C, Piper SN, Suttner S, Lehmann A, Werling C (2001) Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 29 (5): 952-8
51. Hoffmann H, Markewitz A, Kreuzer E, Reichert K, Jochum M, Faist E (1998) Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. Shock 9 (4): 235-40
52. Bahlmann L, Weber C, Heinrichs G et al. (2006) The effect of pentoxifylline on cognitive dysfunction and mood state after open coronary revascularisation while using the heart-lung machine. Anästh Intensivmed 47: 255-263
53. Heinze H, Heringlake M, Bahlmann L, Rosemann C, Misfeld M, Eichler W (2006) Pentoxifylline reduces ICU time in cardiac surgery patients. In: 10th International Congress of Cardiothoracic and Vascular Anesthesia, Book of Abstracts, 29
54. Pereda J, Gomez-Cambronero L, Alberola A et al. (2006) Co-administration of pentoxifylline and thiopental causes death by acute pulmonary oedema in rats. Br J Pharmacol 149 (4): 450-5